PCM
YARW

Prelude Capital Management’s Yarrow Bioscience YARW Stock Holding History

Prelude Capital Management’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,292
Closed -$107K – 1409
2025
Q2 		$107K Sell
1,292
-1,538
-54% -$100K 0.01% 910
2025
Q1 		$224K Buy
2,830
+1,642
+138% +$202K 0.02% 870
2024
Q4 		$199K Sell
1,188
-115
-9% -$15K 0.01% 999
2024
Q3 		$122K Buy
1,303
+2
+0.2% +$190 0.01% 1138
2024
Q2 		$128K Sell
1,301
-591
-31% -$73.7K 0.01% 1074
2024
Q1 		$290K Sell
1,892
-470
-20% -$50.6K 0.02% 910
2023
Q4 		$275K Buy
+2,362
New +$368K 0.02% 774
2018
Q4 		– Hold
0
– -$1K – 2194
2018
Q3 		– Sell
-1
Closed -$30.9K – 1688
2018
Q2 		$16K Buy
+1
New +$38.9K ﹤0.01% 1395

Other funds holding YARW

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Prelude Capital Management's YARW Position: Q3 2025 in Review

Prelude Capital Management sold out of Yarrow Bioscience (YARW) in Q3 2025, closing a stake of 1,292 shares — an estimated $107K sold.

Prelude Capital Management first reported a position in YARW in Q2 2018 and held it in 8 quarters. The position peaked at $290K in Q1 2024. 34 funds tracked by Wall St. Rank hold YARW as of Q3 2025.

  • Prelude Capital Management reported no remaining Yarrow Bioscience position as of Q3 2025 after selling out during the quarter.
  • Prelude Capital Management sold 1,292 Yarrow Bioscience shares in Q3 2025, an estimated $107K.
  • Prelude Capital Management first reported a position in Yarrow Bioscience in Q2 2018 and held it in 8 quarters.
  • Prelude Capital Management's Yarrow Bioscience position peaked at $290K in Q1 2024.
  • 34 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.